Cadila exercises 973 000 warrants of TO3 and EQL receives 6.3 million in capital

Cadila Pharmaceuticals Limited ("Cadila") has exercised 973 000 warrants of TO3.

Cadila received 2 million TO3 with a strike price 6.5 SEK and duration until 15 December 2016 in connection with the directed share issue in October 2015.

A total of 973 000 warrants TO 3 exercised (about 49 percent of all TO 3), which means EQL Pharma will receive approximately 6.3 million SEK. Cadila have, following the subscription of the new shares, 29,9% of capital and votes of EQL Pharma AB.

The new shares are entered as EQL Pharma IA until the issue has been registered with the Swedish Companies Registration Office and Euroclear, which is expected to be completed by the end of January 2017.

After registration is completed, EQL Pharma will have 24,911,666 shares issued. The share capital will amount to SEK 1 361 842.47, an increase of 284 602.50 SEK.

Lund, December 16, 2016

The Board of EQL Pharma AB (publ)

For further information, please contact:

Christer Fåhraeus

CEO EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

E-mail: christer.fahraeus@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB (publ) in brief

EQL Pharma is specialized in developing and selling generic drugs, ie drugs that are medically equivalent to the original medicines. The company currently markets five niche generics in the Swedish and Danish markets, in addition to these, there are a significant pipeline of additional niche generics for launch in 2017 and onwards. The business is currently focused entirely on prescription drugs in the Nordic region. EQL Pharma is based in Lund, employs eight (8) people and is listed on AktieTorget. EQL Pharma conducts extensive development in cooperation with leading contract manufacturers and major pharmaceutical companies in countries including India and China.